125 related articles for article (PubMed ID: 38049618)
1. Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials.
Zografos LJ; Andrews E; Wolin DL; Calingaert B; Davenport EK; Michel A; Latocha M; Schmidt-Ott UM; Lovic N; Brunck LR; Johnson KT; Suzart-Woischnik K
Pharmaceut Med; 2024 Jan; 38(1):63-73. PubMed ID: 38049618
[TBL] [Abstract][Full Text] [Related]
2. Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures.
Zografos LJ; Andrews E; Wolin DL; Calingaert B; Davenport EK; Hollis KA; Schmidt-Ott UM; Petraro P; Vassilev ZP
Pharmaceut Med; 2019 Jun; 33(3):219-233. PubMed ID: 31933286
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures.
Zografos LJ; Andrews E; Wolin DL; Calingaert B; Davenport EK; Hollis KA; Djokanovic N; Racanelli VS; Petraro P; Vassilev ZP
Pharmaceut Med; 2019 Jun; 33(3):235-246. PubMed ID: 31933288
[TBL] [Abstract][Full Text] [Related]
4. Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.
Weber M; Dominguez M; Coscas F; Faure C; Baillif S; Kodjikian L; Cohen SY
BMC Ophthalmol; 2020 May; 20(1):206. PubMed ID: 32450838
[TBL] [Abstract][Full Text] [Related]
5. Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration.
Cohen SY; Dominguez M; Coscas F; Faure C; Baillif S; Oubraham H; Kodjikian L; Weber M;
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):959-969. PubMed ID: 36399178
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial.
Inatani M; Higashide T; Matsushita K; Miki A; Ueki M; Iwamoto Y; Kobayashi M; Leal S;
Adv Ther; 2021 Feb; 38(2):1116-1129. PubMed ID: 33330958
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
Okada AA; Takahashi K; Ohji M; Moon SC; Machewitz T; Sasaki K;
Adv Ther; 2022 Jun; 39(6):2984-2998. PubMed ID: 35503499
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study.
Korobelnik JF; Daien V; Faure C; Tadayoni R; Giocanti-Auregan A; Dot C; Kodjikian L; Massin P
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):521-528. PubMed ID: 31894377
[TBL] [Abstract][Full Text] [Related]
9. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries.
Zografos L; Wolin D; Andrews E; Calingaert B; Balabanova Y; Horvat-Bröcker A; Tarenz C; Suzart-Woischnik K
Expert Opin Drug Saf; 2022 Mar; 21(3):435-446. PubMed ID: 34806928
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET study.
Ogura Y; Iida T; Lee WK; Cheung CMG; Mitchell P; Leal S; Schmelter T; Ishibashi T
Jpn J Ophthalmol; 2021 May; 65(3):344-353. PubMed ID: 33474611
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes.
Sivaprasad S; Ghanchi F; Kelly SP; Kotagiri A; Talks J; Scanlon P; McGoey H; Nolan A; Saddiq M; Napier J; Morgan-Warren P
Eye (Lond); 2023 Aug; 37(12):2527-2534. PubMed ID: 36653595
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME).
Korobelnik JF; Kleijnen J; Lang SH; Birnie R; Leadley RM; Misso K; Worthy G; Muston D; Do DV
BMC Ophthalmol; 2015 May; 15():52. PubMed ID: 25975823
[TBL] [Abstract][Full Text] [Related]
13. Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes.
Eissing T; Stewart MW; Qian CX; Rittenhouse KD
Transl Vis Sci Technol; 2021 Apr; 10(4):9. PubMed ID: 34003985
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
[TBL] [Abstract][Full Text] [Related]
15. Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
Wachtlin J; Eter N; Hasanbasic Z; Keramas G; Rech C; Sachs H; Schilling H; Wiedemann P; Framme C
Graefes Arch Clin Exp Ophthalmol; 2021 Mar; 259(3):601-611. PubMed ID: 32789651
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union.
Patel H; Ton TGN; Davies J; Fear S; Block C; Tanaka K; Gonzalez D; Mutter R; Alfaro-Oliver N; Mendez I; Qizilbash N
Pharmaceut Med; 2021 Nov; 35(6):339-351. PubMed ID: 34877624
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
[TBL] [Abstract][Full Text] [Related]
18. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial.
Garweg JG; Štefanickova J; Hoyng C; Niesen T; Schmelter T; Leal S; Sivaprasad S;
Adv Ther; 2022 Jun; 39(6):2701-2716. PubMed ID: 35412227
[TBL] [Abstract][Full Text] [Related]
19. Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis.
Wang X; He X; Qi F; Liu J; Wu J
Front Pharmacol; 2022; 13():876386. PubMed ID: 35814207
[No Abstract] [Full Text] [Related]
20. Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison.
Ohji M; Lanzetta P; Korobelnik JF; Wojciechowski P; Taieb V; Deschaseaux C; Janer D; Tuckmantel C
Adv Ther; 2020 May; 37(5):2184-2198. PubMed ID: 32222903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
